BRAIN-Biocatalysts Life Science Solutions:
Enzyme Solutions for Small Molecule APIs and Biologics
Your flexible end-to-end enzyme development and scale-up partner for small molecule API and biologics production
At BRAIN-Biocatalysts, we specialise in delivering innovative enzyme solutions tailored for the pharmaceutical industry. Our comprehensive capabilities enable our partners to accelerate drug development, safeguard their intellectual property, and seamlessly scale from enzyme discovery to full-scale production. Whether you're developing next-generation therapies or advancing pharmaceutical processes, we're here to ensure your success at every step of the journey. By leveraging the strengths of both companies, we simplify biocatalysis, delivering tailored, scalable solutions that ensure your product, your IP, and your future are fully supported.
End-to-end partner for enzyme solutions
The only company offering complete adaptable enzyme development and scale-up solutions to support the evolving need of the life science industry
Your Product | Your IP | Your Future
Related Products
Amylase 11MDP
Rapid digestion of starch designed for use in dietary supplement formulations.
Download Data Sheet
Request a Sample
Catalase 929L
Removal of hydrogen peroxide used as a processing step to assist sterilisation of food ingredients.
Download Data Sheet
Request a Sample
Cellulase 13L
A high performance cellulase with beta-glucanase and beta-glucosidase side activities to contribute to a complete cellulose breakdown.
Download Data Sheet
Request a Sample
DELTABREW® AA
Liquid concentrated heat stable alpha-amylase for adjunct brewing, both GM and non-GM versions available
More Information
DELTABREW® BG
Liquid beta-glucanase for viscosity reduction and beer filtration improvement, both GM and non-GM versions available
More Information
Related Media
1 Oct 2024
BRAIN Biotech AG and Biocatalysts Ltd Launch a New Business Initiative to Revolutionise Enzyme Solutions within the Life Science Industry
Combining cutting-edge enzyme discovery, optimisation, and large-scale manufacturing to offer an end-to-end solution for the life sciences industry. BRAIN-Biocatalysts Life Science Solutions addresses critical gaps in the market, providing tailored enzyme solutions with a transparent IP strategy that ensures partners retain full control over their innovations.
Application Solution
Unlocking the benefits of plant oil hydrolysis
Free fatty acids, the fundamental building blocks in many sectors, can vary in chain length and degree of saturation, influencing their functionality and applications. However, the industry has long faced challenges in maximising the yield of free fatty acids while maintaining cost efficiency and environmental sustainability.
16 Sept 2024
Biocatalysts Ltd Launches Lipomod™ 70MDP - Setting A New Standard To Deliver Sustainable Solutions for Oleochemicals Industry with Maximal Production Efficiency
Achieve superior hydrolysis unseen in the market for breaking down plant-derived oils into valuable by-products like glycerol and fatty acids
30 Aug 2024
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
BRAIN Biotech AG, a leading provider of integrated solutions for the biologisation of industry, today published its 9M results of FY2023/2024.
22 Aug 2024
BRAIN Biotech launches MetXtra™
Designed to establish and optimise biocatalytic processes, develop novel enzyme solutions and generate IP or FTO for customers, the cutting edge technologies of MetXtra™ unlock the secrets of the unexplored sequence space.
30 Jul 2024
Biocatalysts Ltd launches new "Plug & Produce" production strains significantly reducing scale-up time and cost
Developing enzyme and protein fermentation processes can be long and expensive and is often reliant on a single partner. Our proprietary "Plug & Produce" platform of microbial fermentation strains can bring product to market quicker, reduce cost and reduce supply chain risk.
23 Jul 2024
The Crucial Role of Phenylalanine Dehydrogenase in Detecting Phenylketonuria
Phenylketonuria (PKU) is genetic disorder resulting from a deficiency in the enzyme phenylalanine hydroxylase for the conversion of the amino acid, phenylalanine to tyrosine. This condition can cause phenylalanine accumulation in the blood and result in neurological damage if left untreated or undiagnosed. Read about the highly specific and sensitive enzymatic method for early detection of PKU.
10 Jun 2024
Enzymes: The Eco-Warriors of Food Manufacturing
As companies increasingly prioritise sustainability, enzymes emerge as unknown heroes, quietly revolutionising the way we produce food.
4 Jun 2024
The Power of Enzymes: Why Hydrolysing Proteins Matters
In the world of biology and biochemistry, the process of hydrolysing proteins using enzymes plays a crucial role in industrial applications, with significant environmental benefits.
30 May 2024
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
Parent company BRAIN Biotech AG, a leading provider of integrated solutions for the biologisation of industry, today published its half year results, 6M 2023/2024.
28 May 2024
Biocatalysts Ltd Introduce Unique Protease Platform for the Manufacture of High Value Collagen Peptides
The launch of two unique protease enzymes, Promod™ 327L and Promod™ 295L, deliver significant efficiency and precision in collagen processing, optimising taste, texture and processibility.
20 May 2024
Biocatalysts Ltd Completes Scale Up of Speciality Enzyme for Large Pharmaceutical Company Utilising its New Chromatography Facility
Newly installed advanced chromatography system at Cardiff site enables the production of high-purity speciality enzymes.
